| 证券代码 | PGNX.O |
| 证券名称 | 普罗基尼克斯制药 |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 1997-11-19 |
| 首发价格(元) | 8 USD |
| 首发数量(股) | 2000000 |
| 首发募资额(元) | 16,000,000.00 USD |
| 首发主承销商 | CIBC Oppenheimer Corp |
| 货币单位 | USD |
| 公司名称 | Progenics Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | One World Trade Center, 47th Floor, New York, New York, USA |
| 成立日期 | 1986 |
| 董事会主席 | Ann MacDougall |
| 公司属地 | United States 美国 |
| 公司网址 | www.progenics.com |
| 电话 | +1 (646) 975-2500 |
| 传真 | +1 (646) 707-3626 |
| 公司简介 | Progenics Pharmaceuticals, Inc. and its subsidiaries develop innovative medicines and other technologies to target and treat cancer. Its pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA and 1095); (2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis tools. Its first commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant. |